Molecular diagnostics play Roka Bioscience Inc. (NASDAQ:ROKA) raised $60 million through the sale of 5 million shares at $12 in an IPO. The price values the company at $211.6 million. Earlier this month, the company said it planned to sell 5 million shares at $14-$16. BofA Merrill Lynch; Leerink Partners; Cowen; and Wedbush PacGrow are underwriters.

Roka markets its Atlas Detection Assays and Atlas instrument in North America to detect foodborne pathogens. Gen-Probe Inc. spun out Roka in 2009. Hologic Inc. (NASDAQ:HOLX) acquired Gen-Probe.

Roka was unchanged on its first day of trading on Thursday.